Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
of Oramed Pharmaceuticals, Inc.
NEW YORK, Feb. 4, 2014
NEW YORK, Feb. 4, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Oramed Pharmaceuticals Inc. ("Oramed" or the
"Company") (NasdaqCM: ORMP). Such investors are advised to contact Peretz
Bronstein or his investor Relation's coordinator Eitan Kimelman at
email@example.com or 212-697-6484.
The investigation concerns whether Oramed and certain of its officers and/or
directors have violated federal securities laws. On Monday, February 3, 2014,
a report was published on TheStreet.com website questioning the integrity and
robustness of the data presented by the Company regarding its Oral Insulin
Pill, with the report calling such data "Completely Worthless".
On this news, shares of Oramed fell $5.32 or 24.08% to close at $16.77.
If you are aware of any facts relating to this investigation, or purchased
shares of Oramed you can assist this investigation by contacting Peretz
Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein,
Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those
who inquire by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC
Press spacebar to pause and continue. Press esc to stop.